

ASX RELEASE

25 March 2021

**Change of Registered Office and Principal Place of Business**

The Company has changed its Registered Office and Principal Place of Business to:

Level 21, 90 Collins Street  
Melbourne VIC 3000

This ASX announcement authorised for release by the Company Secretary.

**For Further Information**

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).